Eisai and Biogen Present Detailed Results from Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer's Disease at AAIC 2018

21:29 EDT 25 Jul 2018 | FinanzNachrichten

TOKYO, July 26, 2018 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced detailed results from a Phase II clinical study (Study 202) of the investigational oral BACE (beta a...

More From BioPortfolio on "Eisai and Biogen Present Detailed Results from Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer's Disease at AAIC 2018"